TC
KPTI icon

TFS Capital’s Karyopharm Therapeutics KPTI Stock Holding History

TFS Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,003
Closed -$987K – 763
2016
Q4 		$987K Buy
+7,003
New +$947K 0.26% 129
2016
Q3 		– Sell
-3,326
Closed -$335K – 869
2016
Q2 		$335K Buy
+3,326
New +$432K 0.06% 559
2015
Q3 		– Sell
-942
Closed -$385K – 974
2015
Q2 		$385K Sell
942
-288
-23% -$124K 0.04% 615
2015
Q1 		$565K Buy
1,230
+537
+77% +$232K 0.06% 512
2014
Q4 		$389K Buy
+693
New +$394K 0.04% 656

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

TFS Capital's KPTI Position: Q1 2017 in Review

TFS Capital sold out of Karyopharm Therapeutics (KPTI) in Q1 2017, closing a stake of 7,003 shares — an estimated $987K sold.

TFS Capital first reported a position in KPTI in Q4 2014 and held it in 5 quarters. The position peaked at $987K in Q4 2016. 80 funds tracked by Wall St. Rank hold KPTI as of Q1 2017.

  • TFS Capital reported no remaining Karyopharm Therapeutics position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 7,003 Karyopharm Therapeutics shares in Q1 2017, an estimated $987K.
  • TFS Capital first reported a position in Karyopharm Therapeutics in Q4 2014 and held it in 5 quarters.
  • TFS Capital's Karyopharm Therapeutics position peaked at $987K in Q4 2016.
  • 80 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.